Memantin Genericon

Memantine Hydrochloride, the active ingredient in Memantin Genericon, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is employed in the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients and is classified as an antidementia agent.

GNH USA supplies Memantin Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across the EU and other global markets.

Memantine Hydrochloride is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity, primarily within the Alzheimer’s disease spectrum.

Alzheimer’s disease (moderate to severe): provides modest improvements in cognition, memory, and global clinical status as measured by standard scales. Behavioral disturbances in Alzheimer’s disease: may lessen agitation, aggression, and psychotic symptoms, supporting caregiver management. Activities of daily living in Alzheimer’s disease: contributes to preservation of functional abilities such as dressing, bathing, and feeding.

Memantine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Constipation - Headache - Confusion

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Memantin Genericon, clinicians should consider several safety aspects.

Renal function: adjust dosing in patients with severe renal impairment. Hepatic function: monitor liver enzymes during therapy. Concurrent NMDA antagonists: avoid co‑administration to reduce risk of additive neurotoxicity. History of seizures: use with caution and monitor closely. Pregnancy and breastfeeding: safety not established; weigh benefits against potential risks. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - Ketamine: additive CNS depression and potential severe psychomotor effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate cognitive side effects. - Central nervous system depressants (e.g., benzodiazepines): may increase dizziness and sedation. - Diuretics: may influence blood pressure control, requiring monitoring.